AMD vs OCGN: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. AMD and OCGN share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined AMD and OCGN exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Advanced Micro Devices (AMD) designs CPUs, GPUs, and adaptive computing chips. The company has two main client-facing CPU lines: Ryzen for consumer PCs and EPYC for data center servers. EPYC has gained significant share against Intel Xeon in cloud and enterprise data centers over the past five years. The Instinct GPU line (MI300X, MI325X, MI350, MI400) is AMD's AI accelerator platform and the primary direct competitor to NVIDIA's data center GPUs.

Full AMD guide

Ocugen, Inc. is a clinical-stage biotechnology company headquartered in Malvern, Pennsylvania, focused on gene and cell therapies for eye diseases. Its core asset is a modifier gene-therapy platform that uses nuclear hormone receptor genes to address disease across many genetic mutations rather than one at a time. The lead program, OCU400, targets broad retinitis pigmentosa in the Phase 3 liMeliGhT trial; OCU410 targets geographic atrophy secondary to dry age-related macular degeneration; and OCU410ST targets Stargardt disease. The company has framed a goal of pursuing three biologics license applications across these programs and also runs earlier-stage work in other modalities.

Full OCGN guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• AMD drivers: Instinct AI GPU ramp; EPYC server share gains.
• OCGN drivers: Lead program advancing toward a regulatory decision; A platform, not a single shot on goal.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: NVIDIA's structural advantages in AI (CUDA ecosystem, manufacturing capacity allocations from TSMC, customer relationships) make AI GPU share gains harder than the hardware comparison alone suggests. For OCGN, ocugen is a speculative, clinical-stage company with no approved products and no meaningful product revenue, so its programs may fail in trials or fall short of regulatory approval.

Pick AMD if you believe its drivers more; OCGN if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the AMD and OCGN guides.

AMD. AMD trades at a premium P/E reflecting the AI accelerator growth story and EPYC share gains. The valuation depends on continued execution against NVIDIA in AI; multiple compresses quickly if Instinct share gains stall.

OCGN. Ocugen is pre-profit and pre-revenue, so traditional earnings metrics do not apply; what matters is cash runway versus burn. Management indicated a roughly $115 million convertible note offering would extend the runway into 2028 against projected operating expenses of about $50 to $60 million per year. Figures are approximate and tied to the asOf date; later raises or spending changes can move them materially.

Headline figures (approximate, early 2026): AMD shows revenue (ttm) ~$30 billion, operating margin ~25% (improving as data center mix grows), net income (ttm) ~$4 billion (GAAP; higher non-GAAP), eps (ttm) ~$2.50; OCGN shows market capitalization ~$475 million (mid-2026), shares outstanding ~339 million, q1 2026 net loss ~$19.2 million, cash and restricted cash (mar 31, 2026) ~$32.2 million.

AMD and OCGN are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined AMD and OCGN exposure against your real portfolio. It is not an investment adviser.